Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Linda J, Landells"'
Publikováno v:
The Lancet Oncology. 20:904-905
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c7e35687265fc1f7dd38709ae52e911b
https://doi.org/10.1016/s1470-2045(19)30351-1
https://doi.org/10.1016/s1470-2045(19)30351-1
Publikováno v:
International Journal of Technology Assessment in Health Care. 33:1-2
INTRODUCTION:The changing regulatory landscape brings new challenges to Health Technology Assessment (HTA). Marketing authorizations are being granted as the evidence base evolves to facilitate timely patient access to promising health technologies.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5138cf2710e2c00a5f17e78bbb2a4805
https://doi.org/10.1017/s0266462317001131
https://doi.org/10.1017/s0266462317001131
Autor:
Andrew Dillon, Linda J Landells
Publikováno v:
JAMA. 319:767
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a111a5f10dbd5f170fe392d98f5ea1a1
https://doi.org/10.1001/jama.2017.20552
https://doi.org/10.1001/jama.2017.20552
Publikováno v:
BMJ. :i5644
We welcome the authors’ creative ideas on the appraisal of cancer drugs.1 But they are wrong to imply that the Cancer Drugs Fund exists only to support observational data collection.2 With the drug industry playing its part through fair pricing, pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a59b92d2a4d066794e61763525af5b15
https://doi.org/10.1136/bmj.i5644
https://doi.org/10.1136/bmj.i5644
Publikováno v:
The Lancet Oncology. 15:381-382
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2562e6d76f1488a52f7e205654c15280
https://doi.org/10.1016/s1470-2045(14)70089-0
https://doi.org/10.1016/s1470-2045(14)70089-0
Publikováno v:
The Lancet Respiratory Medicine. 1:191-192
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e673f47a76a224e0e708b7f688ec4b55
https://doi.org/10.1016/s2213-2600(13)70065-1
https://doi.org/10.1016/s2213-2600(13)70065-1
Autor:
Donna Donigi, Gale, Linda J, Landells, Domenico, Spina, Alan J, Miller, Kate, Smith, Terry, Nichols, Yakov, Rotshteyn, Alfred, Tonelli, Peter, Lacouture, Ronald M, Burch, Clive P, Page, Brian J, O'Connor
Publikováno v:
British journal of clinical pharmacology. 54(5)
To assess the pharmacokinetic and pharmacodynamic profile of the novel PDE4 inhibitor V11294A (3-(3-cyclopentyloxy-4-methoxybenzyl)-6-ethylamino-8-isopropyl-3H purine hydrochloride) in healthy male volunteers.This was a double-blind, single dose, ran
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::fab102809bea3937a5e59edc48d96ee3
https://pubmed.ncbi.nlm.nih.gov/12445026
https://pubmed.ncbi.nlm.nih.gov/12445026